What If We Are Funding Biotech the Wrong Way?
Biotech is often described as capital intensive, high risk, and slow to mature. Those statements are all true, but they are also incomplete. What we are seeing now is not simply the consequence of a difficult sector. It is the result of a deeper misalignment between the nature of scientific…
Biotech Under Pressure: Why Proposed Federal Science Cuts Will Reshape Innovation More Than Any Market Cycle
The proposed removal of approximately $16.6 billion from science, research, public health, and innovation funding is often discussed as a policy issue. For biotechnology leaders, it is a structural risk issue.